
- /
- Supported exchanges
- / US
- / ABT.NYSE
Abbott Laboratories (ABT NYSE) stock market data APIs
Abbott Laboratories Financial Data Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abbott Laboratories (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Abbott Laboratories data using free add-ons & libraries
Get Abbott Laboratories Fundamental Data
Abbott Laboratories Fundamental data includes:
- Net Revenue: 43 843 M
- EBITDA: 11 623 M
- Earnings Per Share: 7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-15
- EPS/Forecast: 1.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abbott Laboratories News

Peter Lynch Detailed Fundamental Analysis - ABT
Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of...


Earnings live: Tesla, Netflix, General Motors, Ford, and P&G to headline third quarter earnings calendar this week
Earnings season is ramping up as Tesla (TSLA) and Netflix (NFLX) report results this week. As of Oct. 17, 12% of S&P 500 companies have reported results, according to FactSet data, and analysts are e...

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk and J&J in focus
U.S. stocks wavered amid increased volatility on Friday but managed to resurge, as Wall Street was rattled by concerns on the health of regional banks and credit risks while the U.S. government shutdo...

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025
Reliability pays. The past few months have shown us how quickly market hype can fade, but companies that have been building value through steady dividend growth and consistent capital investment tell ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.